Yi Zhang

ORCID: 0000-0001-8690-1026
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Breast Lesions and Carcinomas
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer-related Molecular Pathways
  • Estrogen and related hormone effects
  • Spectroscopy Techniques in Biomedical and Chemical Research
  • Metabolomics and Mass Spectrometry Studies
  • Cancer Risks and Factors
  • Cancer Cells and Metastasis
  • Lower Extremity Biomechanics and Pathologies
  • Cardiac Structural Anomalies and Repair
  • Spectroscopy and Chemometric Analyses
  • Nanoparticle-Based Drug Delivery
  • Epigenetics and DNA Methylation
  • Cancer, Hypoxia, and Metabolism
  • Pharmacogenetics and Drug Metabolism
  • Amino Acid Enzymes and Metabolism
  • Knee injuries and reconstruction techniques
  • Microtubule and mitosis dynamics
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Advanced Chemical Sensor Technologies
  • Head and Neck Cancer Studies
  • Drug Transport and Resistance Mechanisms

Huangshi Central Hospital
2025

Hubei Polytechnic University
2025

Second Affiliated Hospital of Nantong University
2024

Nantong University
2024

Second People's Hospital of NanTong
2024

Yangzhou University
2024

Guangdong Provincial People's Hospital
2020-2021

Guangdong Academy of Medical Sciences
2017-2021

Southwest Hospital
2007-2020

Huazhong University of Science and Technology
2020

The US Food and Drug Administration (FDA) is currently developing a guidance for industry to replace previous guidance, "Pharmacokinetics in Patients With Impaired Renal Function—Study Design, Data Analysis, Impact on Dosing Labeling" (renal guidance) issued May 1998. impact of the 1998 renal was assessed following survey 94 new drug applications (NDAs) small-molecule molecular entities (NMEs) approved over past 5 years (2003–2007). results indicate that 57% these NDAs included impairment...

10.1038/clpt.2008.208 article EN Clinical Pharmacology & Therapeutics 2008-11-19

Neoadjuvant chemotherapy (NAC), the systematic given to patients with locally advanced and inoperable breast caner, has been proven be of great clinical values. Many scientific reports confirmed NAC could effectively eliminate sub-clinical disseminated lesions tumor, improve long-term disease-free survival rate cancer (LABC); however, up now, LABC is still a serious issue improved screening early diagnosis. This study, main focus on LABC, investigated values in converting into operable...

10.1038/srep44673 article EN cc-by Scientific Reports 2017-03-22

Heart failure (HF) is the end stage of various heart disease. An increasing number HF centers have emerged in China, which aimed to facilitate standardized, multidisciplinary, and scientific management for patients. The study observe whether establishment center has positive effect on standardized prognosis A before after was performed by randomly collecting a total 300 cases medical records follow-up data database our hospital (Huangshi Central Hospital, Affiliated Hospital Hubei...

10.21037/cdt-24-437 article EN Cardiovascular Diagnosis and Therapy 2025-02-01

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact adding lobaplatin (L) to TE regimen. Here, we show data from 125 (63 62 TEL patients). Four did not all cycles. Two-sided P values that addition L (38.7% vs. 12.7%, = 0.001) significantly increases rate pCR in axilla (TpCR) overall (ORR; 93.5% 73.0%, 0.003). The occurrence...

10.1038/s41467-018-03210-2 article EN cc-by Nature Communications 2018-02-20

This randomized study aimed to compare the clinical efficacy between novel dual tracer composed of indocyanine green (ICG) and blue dye (BD) conventional radioisotope BD for sentinel lymph node (SLN) mapping in patients with breast cancer.This enrolled 471 clinically node-negative primary cancer. All underwent mastectomy, those undergoing biopsy (SLNB) were receive plus (RB group) or ICG (IB group). The detection performances on SLN identification rate, positive counts, sensitivity,...

10.20892/j.issn.2095-3941.2018.0270 article EN cc-by-nc Cancer Biology and Medicine 2018-01-01

Purpose: The study objective was to characterize the prognostic performance of a novel Breast Cancer Index model (BCIN+), an integration BCI gene expression, tumor size, and grade, specifically developed for assessment distant recurrence (DR) risk in HR+ breast cancer patients with one three positive lymph nodes (pN1).Experimental Design: Analysis conducted well-annotated retrospective series pN1 (N = 402) treated adjuvant endocrine therapy or without chemotherapy using prespecified model....

10.1158/1078-0432.ccr-17-1688 article EN Clinical Cancer Research 2017-09-23

Previous studies revealed that patients with early-stage metaplastic breast cancer (MBC) underwent mastectomy more often than breast-conserving therapy (BCT) mainly due to the larger tumor size. This study was performed compare survival outcomes following BCT versus for MBC.Surveillance, Epidemiology, and End Results (SEER) database used identify women diagnosed MBC (T1-3N0-3M0) between 2001 2016, who were treated either or mastectomy. We assessed overall (OS) cancer-specific (BCSS) using...

10.1016/j.breast.2021.03.010 article EN The Breast 2021-04-01

Abstract Background Breast conservation therapy (BCS) after neoadjuvant chemotherapy (NCT) can improve patients’ quality of life. Currently used intraoperative examination for negative margins may not be sufficient to detect microresidual foci, which are a risk factor local recurrence. This study was conducted investigate the shrinking pattern breast cancer and residual tumors as BCS NCT. Methods Ninety women with stage II or III invasive ductal carcinoma who achieved partial response NCT...

10.1186/1477-7819-11-166 article EN cc-by World Journal of Surgical Oncology 2013-07-24

Background: Epirubicin combined with docetaxel is the cornerstone of neoadjuvant chemotherapy (NAC) for breast cancer. The efficacy NAC luminal A cancer patients very limited, and single nucleotide polymorphism one most important factors that influences efficacy. Our study aimed to explore genetic markers epirubicin in Methods: total 421 two stages were enrolled this from 2 centers. Among them 231 included discovery cohort 190 are replication cohort. All received 75mg/m2 on day 1, a 21-day...

10.3389/fonc.2020.571517 article EN cc-by Frontiers in Oncology 2020-09-25

BACKGROUND:The prognostic role of axillary lymph node ratio (LNR) after neoadjuvant chemotherapy (NAC) in breast cancer has not been illuminated. This study was designed to investigate the LNR compared with traditional ypN stage. MATERIAL AND METHODS:A total 306 patients diagnosed positive nodes from January 2007 December 2014 were eligible for this retrospective analysis. All enrolled treated a median 4 cycles NAC followed by mastectomy and level I, II, III dissection (ALND). RESULTS:The...

10.12659/msm.922420 article EN Medical Science Monitor 2020-03-03

Purpose: Tau is a microtubule-associated protein that can be found in both normal and abnormal breast cells.Whether the expression of predict response to neoadjuvant chemotherapy (NACT) still unclear.In this study, we assessed role predicting pathological complete (pCR) NACT for different subtypes cancer.Methods: Four hundred sixty-eight eligible patients were retrospectively recruited our study.The relationship between clinicopathologic factors, including expression, pCR was evaluated using...

10.4048/jbc.2020.23.e11 article EN cc-by-nc Journal of Breast Cancer 2020-01-01

FHL1 is multifunctional and serves as a modular protein binding interface to mediate protein-protein interactions. In skeletal muscle, involved in sarcomere assembly, differentiation, growth, biomechanical stress. Muscle abnormalities may play major role congenital clubfoot (CCF) deformity during fetal development. Thus, identifying the interactions of could provide important new insights into its functional both muscle development CCF pathogenesis. Using proteins derived from rat L6GNR4...

10.1371/journal.pone.0079551 article EN cc-by PLoS ONE 2013-11-12

Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top primary disease, often causing clinical manifestations to be overshadowed disease. Unfortunately, current staging systems do not incorporate myelofibrosis, leading potential treatment delays for SMF. Objectives: To evaluate prognosis patients with multiple myeloma (MM) complicated Design: The study included data and results 208 newly diagnosed (NDMM) who were treated in Affiliated...

10.1177/20406207241292453 article EN cc-by-nc Therapeutic Advances in Hematology 2024-01-01

The present study aims to investigate the impact of traditional Chinese medicine (TCM) on maintaining hemoglobin levels and alleviating renal anemia in patients undergoing maintenance hemodialysis. Renal anemia, a common complication chronic kidney disease (CKD), is primarily caused by deficiency endogenous erythropoietin. TCM has been employed mitigate adverse effects hemodialysis improve quality life for patients. This encompasses comprehensive review literature data-driven analysis...

10.61186/ijkd.8927 article EN Noordanesh. 2024-12-05

541 Background: BCI has been shown to significantly predict risk of overall (10y), early (0-5y), and late ( ≥ 5y) distant recurrence (DR) in HR+, node negative (LN-) breast cancer. A distinct model integrating tumor size grade (BCIN+) was developed for prediction DR HR+ women with 1-3 positive nodes (N1) (Sestak et al., SABCS 2015, P2-08-12). The objective this blinded study independently validate new a large clinical series patients N1 disease. Methods: diagnosed between 1993 2007 5y...

10.1200/jco.2016.34.15_suppl.541 article EN Journal of Clinical Oncology 2016-05-20

576 Background: Although endocrine therapy is the mainstay of management ER+ tumors, optimal neoadjuvant strategy for breast cancer unclear, and improved selection patients chemotherapy (NACT) vs are critical ongoing questions. BCI a gene expression signature that stratifies risk overall (0-10y) late (post-5y) distant recurrence likelihood benefit from extended therapy. Given BCI's proliferation (MGI) estrogen-related (HoxB13/IL17BR) activities, this study investigated its ability to predict...

10.1200/jco.2018.36.15_suppl.576 article EN Journal of Clinical Oncology 2018-05-20

Event Abstract Back to Dual-sensitive hydrogel composite for local release and selective uptake of chemotherapy the treatment breast cancer Yi Zhang1, Joao Conde1, 2, Nuria Oliva1 Natalie Artzi1, 3 1 Massachusetts institute technology, Institute Medical Engineering Science, United States 2 Queen Mary University London, School Materials Kingdom Harvard School, Department Anesthesiology, Introduction: The use drug delivery device, in particular biodegradable polymeric materials, has generated...

10.3389/conf.fbioe.2016.01.01331 article EN cc-by Frontiers in Bioengineering and Biotechnology 2016-01-01

Objective To analyze the clinic pathology features and factor of prognosis affect in triple negative breast cancer(TNBC). Methods A total 329 cases operation approve, immune histochemistry determine HER-2, ER, PR p53 by cancer been analyzed. The patients were divided into TNBC group non-triple (NTNBC). pathologic biology two groups compared. 5-year survival was analyzed Kaplan-Meier method. Results Of 79.03% (260/329) had NTNBC. 20.97% (69/329), average 42 years, prophase...

10.3877/cma.j.issn.1674-0793.2010.04.011 article EN Chin Arch Gen Surg(Electronic Edition) 2010-08-01

Objective To investigate the expression of hypoxia-inducible 1 alpha(HIF-lα)and glucose transporter 1(Glut1)in human breast cancer and its relationship to proliferating cell nuclear antigen (PCNA)protein clinical pathologic factors.Methods Immunohistochemical staining was used measure HIF-lα.Glut1 PCNA in fibroadenoma,usual hyperplasia carcinoma.Results HIF-1α not found fibroadenoma hyperplastic Iesions.In contrast.the positive rate ductal carcinoma situ 55%(DCIS,11/20)and invasive...

10.3760/cma.j.issn.1006-9801.2008.12.007 article EN Zhongliu yanjiu yu linchuang 2008-12-28
Coming Soon ...